ÔÚÁÙ´²¹¤×÷ÖУ¬Æ÷¹ÙÒÆÖ²ºóµÄÃâÒß¼à²â£¬¶ÔÔçÆÚ·¢ÏÖºÍÕï¶ÏÅųⷴӦ£¬¼°Ê±²ÉÈ¡·ÀÖδëÊ©¾ßÓÐÖØÒªÖ¸µ¼ÒâÒ塣Ȼ¶ø£¬¿ª·¢¾«×¼µÄÒÆÖ²¼à²âÊÖ¶ÎÈÔÈ»¾ßÓÐÌôÕ½ÐÔ¡£ÍâÃÚÌå×÷ΪһÖÖ·ÇÇÖÈëÐÔÕï¶Ï¹¤¾ßºÜÈÝÒ×ÔÚÉúÎïÌåÒºÖмì²âµ½£¬²¢ÇÒº¬Óз´Ó³²¡ÀíÉúÀíÌõ¼þµÄÌض¨ºËËá¡¢µ°°×ÖʺÍÖ¬ÖÊ£¬¿É×÷Ϊ¶àÖÖ¼²²¡µÄÕï¶ÏÉúÎï±êÖ¾ÎÆäÔÚÒÆÖ²ºóµÄÅųⷴӦµÄ¼à²âÉÏͬÑùÓµÓо޴óµÄDZÁ¦¡£½ñÌ컪ӯÊӽǷÖÏíÁË5ƪÍâÃÚÌåÔÚÒÆÖ²¼à²âÖеÄÓ¦ÓõݸÀý£¬Ï£ÍûÄÜΪ´ó¼ÒµÄÑо¿ÌṩеÄ˼·¡£

|   ÍâÃÚÌåÓëÐÄÔàÒÆÖ²

2020Ä꣬J Heart Lung TransplantÔÓÖ¾£¨IF:10.247£©^[1]·¢±íÎÄÕ“Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant”·¢ÏÖѪ½¬Ñ­»·Ï¸°ûÍâÄÒÅÝ£¨EVs, Extracellular Vesicle£©±íÃæµ°°×Æ׿É×÷ΪÐÄÔàÒÆÖ²ÅųⷴӦµÄ·ÇÇÖÈëÐÔÉúÎï±êÖ¾Îï¡£

¸ÃÑо¿ÕÐļÁË90Ãû»¼Õߣ¨53¸öѵÁ·¶ÓÁУ¬37¸öÑéÖ¤¶ÓÁУ©£¬ÊÕ¼¯Ñª½¬£¬Í¨¹ý³¬ËÙÀëÐÄ·¨·ÖÀëÍâÄÒÅÝ£¬ÄÉÃ×Á£¾¶·ÖÎö£¨NTA£¬Nanoparticle Tracking Analysis£©ÆÀ¹ÀEVsŨ¶È£¬¶àÖØÁ÷ʽϸ°ûÊõ²â¶¨ÍâÃÚÌå±íÃ濹ԭ¡£½á¹ûÏÔʾ£¬ÓëÒõÐÔ»¼Õߣ¨RO, rejection 0£©Ïà±È£¬ÅųⷴӦ»¼Õߣ¨ACR, Acute Cellular Rejection; AMR, Antibody-Mediated Rejection£©µÄEVsŨ¶ÈÏÔÖøÔö¼Ó£¬Ö±¾¶¼õС£¬ÇÒ¼±ÐÔϸ°ûÅų⻼Õߣ¨AMR£©µÄEVsŨ¶ÈÏà½ÏÓÚ¿¹Ìå½éµ¼µÄÅų⣨ACR£©ÏÔÖøÔö¼Ó(ͼ1A)¡£ÔÚEVs±íÃæµ°°×ÖУ¬CD3¡¢CD2¡¢ROR1¡¢SSEA-4¡¢HLA-IºÍCD41¿ÉÇø·ÖROºÍAMR£¬¶øHLA-II¡¢CD326¡¢CD19¡¢CD25¡¢ CD20¡¢ROR1¡¢SSEA-4¡¢HLA-IºÍCD41b¿ÉÇø·ÖROÓëACR(ͼ1B)¡£Í¨¹ýROC·ÖÎö֤ʵÁËÿ¸öµ¥Ò»±êÖ¾ÎïÕï¶ÏACM£¨Í¼1C£©ºÍAMR£¨Í¼1D£©µÄ¿É¿¿Õï¶ÏÐÔÄÜ£¨ÇúÏß·¶Î§ÏµÄÃæ»ý£¬0.727-0.939£©¡£Ëæºó£¬¸ù¾Ý²îÒìEVsµ°°×±í´ïÔÚ½¨Á¢ÁËÕï¶ÏÄ£ÐÍ£¬¸ÃÄ£ÐÍÄܹ»Çø·Ö½ÓÊÜÅųâµÄ»¼ÕߺÍûÓÐÅųâµÄ»¼Õߣ¬ÔÚÒ»¸ö¶ÀÁ¢µÄÍⲿ¶ÓÁÐÖÐÑéÖ¤µÄ׼ȷ¶È´ïµ½ÁË86.5%£¨Í¼1E£©¡£×ÜÌå½á¹û±íÃ÷£¬Ñ­»·EVs×÷Ϊ±íÕ÷ÐÄÔàͬÖÖÒìÌåÒÆÖ²ÅųⷴӦµÄй¤¾ß·Ç³£ÓÐÇ°¾°¡£

|   ÍâÃÚÌåÓëÉöÒÆÖ²

2021Ä꣬J Am Soc NephrolÔÓÖ¾£¨IF:10.122£©^[2]·¢±íÎÄÕ“Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection”·¢ÏÖ´ÓÄòÒºÖзÖÀë³öµÄÍâÃÚÌå¿ÉÄÜÊÇÉöÒÆÖ²ÅųⷴӦµÄ¿ÉÐÐÉúÎï±êÖ¾Îï¡£
¸ÃÑо¿´Ó175ÃûÉöÒÆÖ²»î¼ìµÄ»¼ÕßÖвɼ¯ÁË220·ÝÄòÒºÑù±¾£¨Í¼2A£©£¬Í¨¹ýÊÔ¼ÁºÐ·½·¨·ÖÀë³öÄòÒºÍâÃÚÌ壬Ëæºó´ÓÕâЩÄÒÅÝÖзÖÀë³öRNA£¬²ÉÓûùÒòоƬ£¨TaqMan OpenArray Human Inflammation Panel£©µÄ·½·¨£¬²¢È·¶¨ÁË15¸ö»ùÒò×é³ÉµÄPanel¿ÉÒÔÇø·ÖÅųⷴӦÊÇ·ñ·¢Éú£¬ROC·ÖÎöÏÔʾAUCΪ0.93£¨95% CI£¬0.87 ÖÁ 0.98£©¡£»ùÓÚÍâÃÚÌåµÄÌØÕ÷µÄÒõÐÔÔ¤²âֵΪ93.3%£¬ÑôÐÔÔ¤²âֵΪ86.2%£¨Í¼2B£©¡£´ËÍ⣬¸ÃÑо¿»¹È·¶¨ÁË5¸ö»ùÒò×é³ÉµÄpanel¿ÉÒÔ½«Tϸ°û½éµ¼µÄÅų⻼Õߣ¨TCMR, T cell–mediated rejection£©Ó뿹Ìå½éµ¼µÄÅų⻼Õߣ¨ABMR, antibody- mediated rejection£©Çø·Ö¿ªÀ´£¨AUCΪ 0.87£»95% CI£¬0.76ÖÁ0.97£©¡£¸ÃÌØÕ÷µÄÒõÐÔÔ¤²âֵΪ90.6%£¬ÑôÐÔÔ¤²âֵΪ77.8%£¨Í¼2C£©¡£ÄòÒºÍâÃÚÌå»ùÒòÌØÕ÷ÔÚÇø·ÖTCMRºÍABMR״̬·½ÃæµÄÇ¿´ó±íÏÖ£¬¿ÉÒÔͨ¹ýÅųýABMRÀ´°ïÖúÍêÉÆÕï¶Ï£¨Í¼2D£©¡£×ÜÖ®£¬À´×ÔÄòÍâÃÚÌåµÄmRNAÌØÕ÷´ú±íÁËÒ»ÖÖÇ¿´óµÄ·ÇÇÖÈëÐÔ¹¤¾ß£¬ÓÃÓÚɸ²éÉöÒÆÖ²ÅųⷴӦ¡£

|   ÍâÃÚÌåÓëÒȵºÒÆÖ²

2017Ä꣬J Clin InvestÔÓÖ¾£¨IF:14.800£©^[3]·¢±íÎÄÕ“Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue”·¢ÏÖ×éÖ¯ÌØÒìÐÔÍâÃÚÌåÉúÎï±êÖ¾Îï¿É¼à²âÒȵºÒÆÖ²ºóµÄÃâÒßÅųⷴӦ¡£

¸ÃÑо¿ÀûÓÃÎÞÐØÏÙµÄÌÇÄò²¡Ð¡ÊóÒÆÖ²È˵ÄÒȵºµÄÒìÖÖÒÆֲģÐͽøÐÐʵÑ飬·¢ÏÖ½ÓÖÖ°×ϸ°ûÓÕµ¼ÃâÒßÅųâµÄÒȵºÒÆÖ²×飨R-xeno£©Ñª½¬ÖÐÍâÃÚÌåµÄŨ¶ÈÓëδÓÕµ¼ÃâÒßÅųâµÄÒȵºÒÆÖ²×飨N-xeno£©ÎÞͳ¼Æѧ²îÒì(ͼ3A)£¬µ«ÊÇR-xeno×éµÄѪ½¬ÖÐHLAÑôÐÔµÄÍâÃÚÌåŨ¶È½ÏN-xeno×éÃ÷ÏÔ½µµÍ(ͼ3B)¡£ÔÚ½ÓÖÖͬԴ°×ϸ°ûÓÕµ¼ÃâÒß·´Ó¦ºó£¬HLAÑôÐÔÍâÃÚÌåÐźÅÃ÷ÏÔϽµ£¬7Ììºó¿Õ¸¹ÑªÌǼ±¾çÉÏÉý(ͼ3C)¡£Ê¹Óÿ¹HLA¿¹ÌåżÁªµÄ´ÅÖé´ÓÊÜÌåѪ½¬Öд¿»¯ÒÆÖ²µÄÒȵºÀ´Ô´µÄÍâÃÚÌ壬·¢ÏÖÃâÒßÅų⵼ÖÂÒȵºÍâÃÚÌåÖÐÄÚ·ÖÃÚ¼¤ËØÒȵºËصÄϽµ(ͼ3D)¡£Ëæºó£¬Í¨¹ý¶Ô´¿»¯µÄÒÆÖ²ÒȵºÔ´ÍâÃÚÌ壨TISEs£©ÓëÒÆÖ²µÄÒȵº×éÖ¯½øÐеĵ°°×ÖʺÍmiRNA³É·Ö·ÖÎö£¬É¸Ñ¡³öÁ˲¿·Ö²îÒì±í´ïµÄmiRNAs(ͼ3E)£¬Í¬Ê±·¢ÏÖÃâÒßÅųⷴӦ»áµ¼ÖÂTISEµ°°×µÄ¸Ä±ä(ͼ3F)¡£×îºó£¬Í¨¹ýÊÕ¼¯ÁÙ´²Ñù±¾·¢ÏÖ³öÏÖÃâÒßÅųâµÄ»¼ÕßHLAÍâÃÚÌåÐźÅÔÚÔ¼100ÌìºóÒ»Ö±ÔÚϽµ£¬ÑªÌÇÔÚ800-1000Ììʱ¼±¾çÉÏÉý(ͼ3G)¡£´ËÍ⣬TISE³É·Ö¿ÉÒÔÔÚÁÙ´²Ñù±¾Öд¿»¯²¢¼ì²âµ½£¬ÇÒ¹©ÌåÍâÃÚÌåµÄѪ½¬·ÖÎöÏÔʾÔÚ²úÉúÃâÒßÅųⷴӦºóHLA-A2ÐźÅÊÇÒõÐÔµÄ(ͼ3H)¡£×ÜÖ®£¬¸ÃÑо¿½á¹û±íÃ÷ÒÆÖ²×éÖ¯½«¹©ÌåÌØÒìÐÔHLAÍâÃÚÌåÊͷŵ½ÊÜÌåÑ­»·ÖУ¬²¢ÇÒ¹©ÌåÍâÃÚÌå³É·ÖµÄ¶¨Á¿ºÍ·ÖÎö»ò¿É×÷Ϊ¼à²âÅųⷴӦµÄÉúÎï±êÖ¾Îï¡£

|   ÍâÃÚÌåÓë·ÎÒÆÖ²

2021Ä꣬TransplantationÔÓÖ¾£¨IF:4.934£©^[4]·¢±íÎÄÕ“Circulating Donor Lung-Specific Exosome Profiles Enable Noninvasive Monitoring of Acute Rejection in a Rodent Orthotopic Lung Transplantation Model”·¢ÏÖÑ­»·¹©Ìå·ÎÌØÒìÐÔÍâÃÚÌåÌØÕ÷Äܹ»ÔÚÄö³Ý¶¯Îïԭλ·ÎÒÆֲģʽ϶Լ±ÐÔÅųâ½øÐÐÎÞ´´¼à²â¡£

¸ÃÑо¿½«±í´ïÈËÀàCD63-GFPµÄWistarת»ùÒò´óÊóµÄ×ó·ÎÒÆÖ²µ½MHC´íÅäµÄLewis´óÊó»òͬԴ¶ÔÕÕÖУ¬ÔÚÒÆÖ²ºó4СʱÖÁ10ÌìÖ®¼äÊÕ¼¯ÊÜÌå´óÊóѪ½¬£¬²¢Í¨¹ý³ß´çÅÅ×èÖù²ãÎö·ÖÀëÍâÃÚÌ壬ͨ¹ýÄÉÃ×Á÷ʽ¶ÔÑ­»·¹©ÌåÍâÃÚÌå½øÐзÖÎö£¬·¢ÏÖ¼±ÐÔͬÖÖÒìÌåÒÆÖ²Åųâ¶ÔÊÜÌå´óÊóÍâÖÜѪѭ»·ÖеÄÍâÃÚÌå×ÜÁ¿Ã»ÓÐÓ°Ï죨ͼ4A£©£¬Ñ­»·¹©ÌåÌØÒìÐÔÍâÃÚÌåÆ×Ԥʾ×Å×éÖ¯²¡ÀíѧÒÆÖ²ÎïËðÉËÇ°µÄÔçÆÚ¼±ÐÔÅųⷴӦ£¬·¢ÉúÒÆÖ²ÅųâµÄÊÜÌå´óÊóµÄѪ½¬Öй©ÌåÍâÃÚÌåÐźÅÔÚµÚ1Ìì´ïµ½·åÖµ£¬µ«ÔÚµÚ2ÌìÏÔ×ÅϽµ£¬µ½µÚ3Ì죬ÔÚ×éÖ¯²¡Àíѧ³öÏÖÅųⷴӦ֮ǰ£¬¹©Ìå·ÎÌØÒìÐÔhCD63ÍâÃÚÌåÐźŽµµÍÖÁÒÆֲǰ»ùÏßÖµ£¨Í¼4B£©¡£ÔÚ·¢ÉúÅųâµÄÇé¿öÏ£¬ÔÚÒÆÖ²ºó4Сʱ£¬Í¨¹ýµ°°×ÖÊÓ¡¼£ÏÔʾhCD63ºÍGFPµÄ¸»¼¯µÄÍâÃÚÌåCD63¸ß±í´ï£¬µ«ÔÚÒÆÖ²ºó3Ìì¼ì²â²»µ½Ðźţ¨Í¼4C£©¡£²ÉÓÃÄÉÃ׿ÅÁ£Á÷ʽϸ°ûÊõÁ¿»¯Ñ­»·¹©Ìå·ÎÍâÃÚÌå·¢ÏÖ£¬ÔÚÅųâ×éÖУ¬ÒÆÖ²ºó4СʱºÍ1Ì칩Ìå·ÎÌØÒìÐÔÍâÃÚÌåÔö¼Ó£¬µ«ÐźÅÔÚÒÆÖ²ºóµÚ3Ìì»Ö¸´µ½ÒÆֲǰ»ùÏߣ¨Í¼4D£©¡£ÔÚ·ÇÅųâ×éÖУ¬FACS¼ì²âÔÚÊÜÌåÖÐÏÔʾ³öÎÈ̬¹©ÌåÍâÃÚÌåÐźţ¨Í¼4E£©¡£×ÜÖ®£¬Ñ­»·¹©Ìå·ÎÌØÒìÐÔÍâÃÚÌåÌØÕ÷Äܹ»ÔÚ·ÎͬÖÖÒìÌåÒÆÖ²ÎïËðÉ˵Ä×é֯ѧ±íÏÖ֮ǰ¼°Ôç·¢ÏÖ¼±ÐÔÅųⷴӦ¡£

|   ÍâÃÚÌåÓëϸ°ûÒÆÖ²

2019Ä꣬Science Translational MedicineÔÓÖ¾£¨IF:17.956£©^[5]·¢±íÎÄÕ“Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium”·¢ÏÖÊÜÌåѪ½¬Öж¨Á¿ºÍ±íÕ÷ÒÆֲϸ°ûÑÜÉúµÄÍâÃÚÌ彫Äܹ»¶ÔÒÆֲϸ°ûµÄ»îÐÔ½øÐпɿ¿µÄ¡¢·ÇÇÖÈëÐԵļà²â¡£

Ñо¿ÈËԱʹÓÃÁËÒ»ÖÖÈË-´óÊóÒìÖÖÐļ¡¹£ËÀÄ£ÐÍ£¬±È½ÏÁËÁ½ÖÖÑо¿½Ï¶àµÄ×æϸ°ûÀàÐÍ£ºÐļ¡À´Ô´Ï¸°û£¨CDCs£©ºÍc-kit+ÐÄÔà×æϸ°û£¨CPC£©£¨Í¼5A£©£¬·¢ÏÖÔÚÌåÄÚÔÙÉúÄÜÁ¦²â¶¨ÖУ¬CPC±íÏÖÓÅÓÚCDC£¨Í¼5B£©¡£ÎªÁËÔÚÌåÄÚ·ÇÇÖÈëÐԵؼà²âÒÆÖ²µÄCDC»òCPCµÄ»îÐÔ£¬Ñо¿ÈËÔ±²ÉÓóߴçÅÅ×èµÄ·½·¨´ÓÊÜÌå×ÜѪ½¬Öд¿»¯ÁË×æϸ°ûÌØÒìÐÔÍâÃÚÌ壬²¢·¢ÏÖÒÆÖ²ºó7Ì죬ÓëCDCÌØÒìÐÔÍâÃÚÌåÏà±È£¬Ñª½¬CPCÌØÒìÐÔÍâÃÚÌåµÄŨ¶ÈÔö¼ÓÔ¼Á½±¶£¨Í¼5C£©¡£ÉúÎïÐÅϢѧµÄͨ··ÖÎöδÄܽ«CPC»òCDCϸ°ûmRNAÓë¹Û²ìµ½µÄÐļ¡ÐÞ¸´ÁªÏµÆðÀ´£¬µ«ÓëÊÜÌåѪ½¬Öд¿»¯µÄCPCÍâÃÚÌåµÄmiRNAÓйأ¨Í¼5D£©¡£×ÜÖ®£¬¸ÃÑо¿Ñо¿ÁËCDCºÍCPCµÄÐÄÔàÐÞ¸´Ç±Á¦£¬ÑéÖ¤Á˸É/×æϸ°ûÌØÒìÐÔÍâÃÚÌåµÄ¼à²âDZÁ¦£¬²¢Ö¤Ã÷ÍâÃÚÌåmiRNA·´Ó³ÁËÒÆÖ²¸Éϸ°ûµÄ¹¦ÄÜÐÔÐļ¡ÐÞ¸´£¬ÕâЩ·¢ÏÖÖ¤Ã÷ÁËÑ­»·ÖÐ×æϸ°ûÌØÒìÐÔÍâÃÚÌå×÷ΪҺÌå»î¼ìµÄDZÁ¦£¬ÆäΪÒÆֲϸ°ûµÄ״̬ÌṩÁË·ÇÇÖÈëÐÔ¼à²âµÄ·½°¸¡£

|   »ªÓ¯ÊÓ½Ç

ÉÏÊöµÄ5¸öÑо¿°¸ÀýÎÒÃÇ¿ÉÒÔ¿´µ½£¬ÍâÃÚÌåÔÚÒÆÖ²¼à²â·½ÃæÓµÓо޴óµÄÓ¦ÓÃÇ°¾°¡£»ªÓ¯ÊÓ½ÇС±àͨ¹ý¶ÔÒÆÖ²Ïà¹ØµÄÎÄÏ×µÄÕûÀí£¬¾«Ñ¡ÁËÉÏÊö5ƪΪ´ó¼Ò½øÐÐÁ˽âÎö£¬Í¬Ê±£¬ÎÒÃÇÒ²¸øÔÚÒÆÖ²¼à²âÕâÒ»¿é¸ÐÐËȤµÄ¿ÆÑй¤×÷ÕßÌṩÁËһЩ½¨Ò飺

1¡¢ÍâÃÚÌåÔÚÒÆÖ²¼à²âÕâÒ»¿éÄ¿Ç°µÄÑо¿Ïà¶Ô½ÏÉÙ£¬¶ÔÓںܶàÒÆÖ²¿ÆµÄÒ½ÉúÀ´ËµÊÇÒ»¸ö·Ç³£ºÃµÄ»ú»á£¬ÍâÃÚÌåÔÚÉöÒÆÖ²¡¢·ÎÒÆÖ²¡¢¸ÎÒÆÖ²¡¢ÐÄÔàÒÆÖ²£¬ÒȵºÒÆÖ²£¬ÒÔ¼°Ï¸°ûÒÆÖ²µÈ·½ÃæÈÔÓкܴóµÄÍÚ¾ò¿Õ¼ä£¬ÎÞÂÛÊDZêÖ¾ÎïÑо¿»¹ÊÇ»úÖÆÑо¿£¬¾ùÓкܺõÄÍ»ÆƵ㡣

2¡¢ÍâÃÚÌåÖк¬ÓÐÌض¨ºËËá¡¢µ°°×ÖʺÍÖ¬ÖÊ£¬¾ù¿É×÷ΪÎÒÃÇÑо¿µÄ±êÖ¾Îï·Ö×Ó»ò¹¦ÄÜ·Ö×Ó£¬ÎÒÃÇ¿ÉÒÔͨ¹ýµ°°×ÖÊ×éѧ¡¢×ªÂ¼×éѧ¡¢¿¹ÌåоƬ¡¢´úл×éѧµÈ¸ßͨÁ¿µÄɸѡ·½·¨À´È·¶¨²îÒì±í´ïµÄ·Ö×Ó×÷ΪÎÒÃǵÄÑо¿¶ÔÏó£¬ÓÃÓÚÒÆÖ²ºóµÄÅųâ¼à²â¡£

3¡¢ÍâÃÚÌåµÄÌáÈ¡¶ÔÓÚÍâÃÚÌåµÄºóÐø·ÖÎöÖÁ¹ØÖØÒª£¬ÎÒÃÇ¿ÉÒÔ¿´µ½ÎÄÏ×Ò»ºÍ¶þ·Ö±ð²ÉÓÃÁ˳¬ËÙÀëÐÄ·¨ºÍÊÔ¼ÁºÐµÄ·½·¨£¬ÎÄÏ×Èý¡¢ËÄ¡¢Îå¾ù²ÉÓÃÁ˳ߴçÅÅ×èµÄ·½·¨¡£¶ø³ß´çÅÅ×è·¨Ïà¶ÔÀ´Ëµ¿ÉÒÔ·ÖÀë³ö¸ü¸ß´¿¶ÈºÍ»îÐÔµÄÍâÃÚÌå¡£

|   k8¿­·¢(Öйú)-ÍâÃÚÌåÑо¿·þÎñ

k8¿­·¢(Öйú)×÷ΪÍâÃÚÌå·þÎñÁìÓòµÄר¼Ò£¬ÓµÓжÀÌصÄϵͳÐÔ·þÎñÓÅÊÆ£¬¿ÉʵÏÖÍâÃÚÌåÑо¿µÄ“һվʽ·þÎñ”¡£¾­¹ý½ü10ÄêµÄÎȲ½·¢Õ¹£¬k8¿­·¢(Öйú)µÄÍâÃÚÌå·þÎñ²úÆ·Ò²ÒÑÀ©Õ¹µ½ÁËÍâÃÚÌåÑо¿µÄ·½·½ÃæÃ棬°üÀ¨µ«²»ÏÞÓÚ£ºÍâÃÚÌåµÄÈýÏî¼ø¶¨£¨µç¾µ¡¢WB¡¢NTA£©¡¢ÍâÃÚÌåµ°°××éɸѡ£¨lable free¡¢DIA¡¢PRM¡¢MRM£©¡¢ÍâÃÚÌåºËËáɸѡ£¨miRNA¡¢RNAȫת¼×飩¡¢ÍâÃÚÌåÄÉÃ×Á÷ʽ¼ì²â¡¢ÍâÃÚÌåµçת£¨Ò©Îï·Ö×Ó¡¢ºËËᣩ¡¢ÍâÃÚÌåϸ°û&¶¯Î﹦ÄÜʵÑ飨PKH26/DiR/Á¿×ӵ㡢ӫ¹âʾ×Ù£©µÈµÈ¡£

·á¸»È«ÃæµÄÍâÃÚÌ幦ÄÜÑо¿Êֶξ¡ÔÚk8¿­·¢(Öйú)µÄÎäÆ÷¿â£¨ÏÂͼ±êºìɫΪk8¿­·¢(Öйú)ÌØÉ«·þÎñ£©£¬¿ìÀ´Ò»Ì½¾¿¾¹£¬ÓлªÓ¯ÖúÁ¦£¬¼ÓËÙÄãµÄÍâÃÚÌåÏîÄ¿Ñо¿£¡

|   Ïà¹ØÎÄÏ×

[1]. Castellani C, Burrello J,Fedrigo M, et al. Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant. [J]. The Journal of Heart and Lung Transplantation, 2020 Oct;39(10):1136-1148.

[2]. Fekih R E, Hurley J, Tadigotla V, et al. Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. [J]. Journal of the American Society of Nephrology, 2021: ASN.2020060850.

[3]. Vallabhajosyula P, Korutla L, Habertheuer A, et al. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue.[J]. Journal of Clinical Investigation, 2017, 127(4):1375-1391.

[4]. Andreas Habertheuer, Chirag Ram, et al. Circulating Donor Lung-Specific Exosome Profiles Enable Noninvasive Monitoring of Acute Rejection in a Rodent Orthotopic Lung Transplantation Model. [J]. Transplantation. 2021 May 14.

[5]. Saha P, Sharma S,Korutla L,et al. Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium.[J].Science Translational Medicine, 2019, 11(493):eaau1168.

Á˽â¸ü¶à»ªÓ¯Êӽǽâ¶Á£¬»¶Ó­¹Ø×¢“k8¿­·¢(Öйú)”¹«ÖÚºÅ